STOCK TITAN
  1. Home
  2. News
  3. DRTS

Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part in a fireside chat at the Guggenheim Radiopharmaceuticals Day in New York City on Monday, May 15th, 2023.

Event:Guggenheim Radiopharmaceuticals Day
Date:Monday, May 15th, 2023
Time:11:20 AM ET
Location:New York, NY
Webcast:Link

Mr. Levy will also be available for 1x1 investor meetings at the conference. Please reach out to your Guggenheim representative to schedule.

About Alpha Tau Medical, Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Investor Relations Contact:
IR@alphatau.com


Stock DRTS logo
Alpha Tau Medical Ltd

NASDAQ:DRTS

DRTS Rankings

#3875 Ranked by Market Cap
#3415 Ranked by Stock Gains
N/A Ranked by Dividends

DRTS Latest News

Mar 25, 2024
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
Mar 7, 2024
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
Feb 26, 2024
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
Dec 20, 2023
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 29, 2023
Alpha Tau to Participate in Sidoti Small-Cap Conference

DRTS Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing

About DRTS

alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.